Meander Medical Center

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Diffuse large B-cell lymphoma2 trials
• Gastric and oesophageal cancer2 trials
• Acute myeloid leukaemia1 trial
• Bladder cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Myelodysplastic syndromes1 trial
• Parkinson disease1 trial

Phase

• Phase 24 trials
• Phase 11 trial
• Phase 31 trial

Status

• Active, not recruiting5 trials
• Completed2 trials
• Recruiting2 trials
• Not yet recruiting1 trial

Lead sponsor

• Stichting Hemato-Oncologie voor Volwassenen Nederland3 trials
• Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1 trial
• Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting1 trial
• Meander Medisch Centrum1 trial
• Prospective Bladder Cancer Infrastructure Foundation1 trial
• and 3 more

Running trials

• Active, not recruiting

  First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow minimal residual disease (NEXT STEP trial)

  NCT04639362· Phase 2· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Source

• Recruiting

  The Effect of exeRcise And Diet on Quality of Life in Patients With Incurable Cancer of Esophagus and Stomach (RADICES)

  NCT06138223· Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)· Source

  Contact: Ruben Goedegebuure, MD

• Recruiting

  Performance and prognostic value of 68Ga-FAPI PET/CT in non-small cell lung cancer (NSCLC)

  2023-503985-21-00· Phase 1· Meander Medisch Centrum· Source

• Active, not recruiting

  Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission

  NCT05502250· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Recruiting

  Prospective Bladder Cancer Infrastructure (ProBCI)

  NCT04503577· Prospective Bladder Cancer Infrastructure Foundation· Source

  Contact: A. Richters, PhD

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

  NCT03463057· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly diagnosed high grade B cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements

  NCT03620578· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  Multicenter Implementation of E-monitoring in Parkinson's Disease

  NCT05164783· Zuyderland Medisch Centrum· Source

• Completed

  Laparoscopic Versus Open Gastrectomy for Gastric Cancer

  NCT02248519· UMC Utrecht· Source